Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Times Interest Earned (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Times Interest Earned for 9 consecutive years, with -$1.41 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Times Interest Earned rose 49.35% year-over-year to -$1.41, compared with a TTM value of -$1.98 through Dec 2025, up 38.02%, and an annual FY2025 reading of -$1.98, up 38.02% over the prior year.
  • Times Interest Earned was -$1.41 for Q4 2025 at Karyopharm Therapeutics, down from -$1.38 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $5.91 in Q4 2021 and bottomed at -$10.28 in Q1 2021.
  • Average Times Interest Earned over 5 years is -$4.31, with a median of -$5.13 recorded in 2023.
  • The sharpest move saw Times Interest Earned skyrocketed 212.85% in 2021, then crashed 197.3% in 2022.
  • Year by year, Times Interest Earned stood at $5.91 in 2021, then crashed by 197.3% to -$5.76 in 2022, then decreased by 5.82% to -$6.09 in 2023, then surged by 54.16% to -$2.79 in 2024, then skyrocketed by 49.35% to -$1.41 in 2025.
  • Business Quant data shows Times Interest Earned for KPTI at -$1.41 in Q4 2025, -$1.38 in Q3 2025, and -$2.17 in Q2 2025.